Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma.
Marion Alhenc-GelasRomain CohenPascale CerveraJean-Christophe VaillantThierry AndréPublished in: Case reports in gastrointestinal medicine (2019)
Pancreatic adenocarcinoma remains a cancer associated with a poor prognosis. For locally advanced pancreatic cancer (LAPC), median overall survival is approximately 16 months. Here we report the case of a 52-year-old LAPC patient treated with chemotherapy followed by chemoradiotherapy that was associated with a 14-year complete remission. A peritoneal relapse was then observed and chemotherapy was undergone until the patient died of infectious complications, 17 years after his diagnosis. The tumor was found KRAS, TP53, BRCA1, and BRCA2 wild-type. This KRAS wild-type LAPC-long survivor case report emphasizes the need to develop molecular approaches to predict LAPC patients' prognosis.
Keyphrases
- wild type
- locally advanced
- case report
- poor prognosis
- rectal cancer
- neoadjuvant chemotherapy
- squamous cell carcinoma
- radiation therapy
- end stage renal disease
- long non coding rna
- newly diagnosed
- phase ii study
- ejection fraction
- chronic kidney disease
- papillary thyroid
- free survival
- peritoneal dialysis
- clinical trial
- rheumatoid arthritis
- single molecule
- ulcerative colitis
- double blind